Saturday, July 11, 2026

Drug profile · INN

imlunestrant

imlunestrant (INLURIYO) is an FDA-listed pharmaceutical active ingredient.

EMA: approved Antineoplastic and immunomodulating agents (L02) L02BA
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — imlunestrant
Class
Antineoplastic and immunomodulating agents (L02)
Route
Patents
0
Programs
0
Data quality
0.83

Quick answer

imlunestrant (INLURIYO) is an FDA-listed pharmaceutical active ingredient.

Key facts

INN imlunestrant
Brand INLURIYO
Therapeutic class Antineoplastic and immunomodulating agents (L02)
ATC code L02BA

Approval history

Authority Status Date
EMA approved

Related & competitor drugs

  1. abiraterone acetate Antineoplastic and immunomodulating agents (L02)
  2. anagrelide Antineoplastic and immunomodulating agents (L01)
  3. apremilast Antineoplastic and immunomodulating agents (L04)
  4. arsenic trioxide Antineoplastic and immunomodulating agents (L01)
  5. axitinib Antineoplastic and immunomodulating agents (L01)
  6. azacitidine Antineoplastic and immunomodulating agents (L01)

Frequently asked questions

What is imlunestrant?

imlunestrant (INLURIYO) is an FDA-listed pharmaceutical active ingredient.

What is the brand name for imlunestrant?

INLURIYO is a marketed brand name for imlunestrant. Check FDA Drugs@FDA for the current US label holder and prescribing information.